The topic of estimands is an important and relatively new one in clinical development and the paper by Leuchs et al 1 should be commended for its contribution to this subject area. The PSI/ EFSPI Working Group (WG) on Estimands finds much to agree with-particularly in the area of sensitivity analysesand would like to take the opportunity to expand on some areas whilst also highlighting various nuances.
The assessment of the WG is that the trial objectives are a key component in choosing an estimand and that defining these objectives represents an important first step in the process. This augments the Leuchs et al process ( Figure 1 1 ) to include trial objectives as follows: (1) trial objectives, (2) estimand(s), (3) clinical trial design, (4) method of analysis, and (5) sensitivity analysis. The recent focus on estimands appears to be driven by a need to address deficiencies in clinical trial design and trial objectives, and in the resulting linkage to the primary analysis. Therefore, estimands provide the additional level of detail required to implement the objective(s) and bridge a gap between the objectives and the methods chosen for the primary analysis of the primary endpoint. As such, they help clarify assumptions that may be needed at the analysis stage.
The trial design should enable the method of analysis to fully address the estimands and objectives. If this is not possible, the objective, estimands, and design may need to be refined to ensure consistency. The WG therefore views the process flow as iterative, as opposed to strictly linear, whereby close examination of the estimands by the clinical development team could lead to refinement of the objectives and design. This iterative process is consistent with the modelling and simulation approach to clinical program development and trial design where various assumptions are explored iteratively, including dose response, patient characteristics, protocol adherence/missing data patterns, etc. 2 The WG's view is that part of the current problem is actually the lack of detail around the definition of trial objectives. ICH E8 states that ''the objective(s) of the study should be clearly stated and may include exploratory or confirmatory characterisation of safety and/or efficacy and/or assessment of pharmacokinetic parameters and pharmacological, physiological, biochemical effects.'' 3(p.9) The WG recommends that a better definition of objective(s) be developed that advances thinking, brings clarity, and establishes greater linkage.
Clinical trials are multifaceted and expensive, and it is unrealistic to restrict a study to a single estimand. Consistent with the latest thinking that potential label claims require the specification of secondary endpoints that are controlled for multiplicity, 4 the WG recommends that clearly defined secondary estimands should also be required to support label claims. More generally, all protocols should include a description as to how each estimand addresses the objectives.
Leuchs et al 1 presented examples of how estimands can be applied to depression and stroke. The WG agrees that shared examples are required to raise awareness and understanding within the scientific community and recommends that future regulatory therapeutic guidelines provide details of specific estimands for specific objectives and designs.
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